drugset / Trial / NCT01258816

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

NCT01258816

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the pharmacokinetics (PK) and cardiac properties of elacytarabine in patients with relapsed or refractory Acute Myeloid Leukaemia (AML). The efficacy and tolerability of elacytarabine will also be assessed.

Timeline

Start
2010-10
Primary completion
2013-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Elacytarabine Small molecule 2000 mg/m2 Intravenous